Bayer Net Profit Surges Driven by Growth in Agricultural Division
By Adria Calatayud
Bayer reported a sharply higher first-quarter net profit, aided by a gain from the sale of an antibiotics business and stronger underlying earnings at its agricultural division.
The German agricultural-and-pharmaceutical group said Tuesday that net profit for the first quarter was 2.76 billion euros ($3.25 billion) compared with 1.30 billion euros for the same period last year, when its results were hit by litigation provisions. The company also said it booked net special gains of 324 million euros mainly linked to the sale of its Avelox antibiotics business.
After years of legal battles that prompted Bayer to book multibillion-dollar provisions, the company is looking to contain the litigation over Roundup--the world's most widely used weedkiller--in 2026.
Quarterly sales were 13.405 billion euros, up 4.1% when excluding currency and portfolio changes. Analysts had forecast sales at 13.42 billion euros, according to consensus estimates compiled by Vara Research.
Bayer reported organic growth in its agricultural and consumer-health businesses that offset a decline in its pharmaceutical division.
Earnings before interest, taxes, depreciation and amortization excluding special items rose 9% to 4.45 billion euros. Analysts expected the metric at 3.93 billion euros.
Bayer confirmed its full-year outlook adjusted for currency changes.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
May 12, 2026 02:10 ET (06:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States